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Introduction:  Infection  remains  a  major  complication  among  heart  transplant  (HT)  recipients,
causing approximately  20%  of  deaths  in  the  first  year  after  transplantation.  In  this  popula-
tion,  Aspergillus  spp.  can  have  various  clinical  presentations  including  invasive  pulmonary
aspergillosis  (IPA),  with  high  mortality  (53-78%).
Objectives:  To  establish  the  characteristics  of  IPA  infection  in  HT  recipients  and  their  outcomes
in our  center.
Methods:  Among  328  HTs  performed  in  our  center  between  1998  and  2016,  we  identified  five
cases of  IPA.  Patient  medical  records  were  examined  and  clinical  variables  were  extracted.
Results:  All  cases  were  male,  and  mean  age  was  62  years.  The  most  common  indication  for  HT
was  non-ischemic  dilated  cardiomyopathy.  Productive  cough  was  reported  as  the  main  symp-
tom.  The  radiological  assessment  was  based  on  chest  X-ray  and  chest  computed  tomography.
The  most  commonly  reported  radiographic  abnormality  was  multiple  nodular  opacities  in  both
techniques.  Bronchoscopy  was  performed  in  all  patients  and  Aspergillus  fumigatus  was  iso-
lated  in  four  cases  on  bronchoalveolar  lavage  culture.  Treatment  included  amphotericin  in  four
patients,  subsequently  changed  to  voriconazole  in  three,  and  posaconazole  in  one  patient,  with
total  treatment  lasting  an  average  of  12  months.  Neutropenia  was  found  in  only  one  patient,
renal  failure  was  observed  in  two  patients,  and  concurrent  cytomegalovirus  infection  in  three
patients.  All  patients  were  alive  after  a  mean  follow-up  of  18  months.
Conclusions:  IPA  is  a  potentially  lethal  complication  after  HT.  Early  diagnosis  and  prompt  initi-
ation of  aggressive  treatment  are  the  cornerstone  of  better  survival.sa  de  Cardiologia.  Published  by  Elsevier  España,  S.L.U.  
 under CC BY-NC-ND license
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Aspergilose  pulmonar  invasiva  nos  recipientes  de  transplantes  cardíacos:  está  a
mortalidade  a  decrescer?
Resumo
Introdução: A infeção  continua  a  ser  uma  complicação  major  nos  recipientes  para  transplante
cardíaco (TC),  causando  cerca  de  20%  de  mortes  no  primeiro  ano  após  o  transplante.  Nestes
doentes,  o  Aspergillus  species  pode  levar  a  várias  apresentações  clínicas  incluindo  a  aspergilose
pulmonar  invasiva  (API),  com  uma  mortalidade  elevada  (53%  a  78%).
Objetivos: Estabelecer  as  características  da  infeção  por  API  nos  recipientes  para  TC  e  os
respetivos resultados  no  nosso  serviço.
Métodos: Dos  328  transplantes  cardíacos  realizados  no  nosso  centro  entre  1998  e  2016,  iden-
tificámos cinco  casos  de  API.  Foram  examinados  os  registos  dos  doentes  e  foram  identificadas
variáveis  clínicas.
Resultados:  Em  todos  os  casos  os  doentes  eram  do  sexo  masculino  com  idade  média  de  62  anos.
A indicação  mais  comum  para  TC  foi  a  miocardiopatia  não  isquémica  dilatada.  O  principal  sin-
toma  foi  tosse  produtiva.  A  avaliação  radiológica  baseou-se  na  radiografia  e  na  TAC  torácicas.
A alteração  radiológica  mais  comum  foi  a  densidade  nodular  múltipla  em  ambas  as  técnicas.
A broncoscopia  foi  realizada  em  todos  os  doentes  e  o  Aspergillus  fumigatus  foi  isolado  em  qua-
tro  casos  de  cultura  BAL.  O  tratamento  incluiu  anfotericina  em  quatro  doentes  com  alteração
subsequente para  voriconazol  em  três  doentes  e  posaconazol  num  doente,  tendo  o  tratamento
durado  uma  média  de  12  meses.  A  neutropenia  foi  encontrada  num  doente  apenas,  a  insuficiên-
cia  renal  foi  observada  em  dois  doentes  e  a  infeção  por  CMV  ocorreu  em  três  doentes.  Todos  os
doentes  sobreviveram  após  seguimento  de  18  meses.
Conclusão:  A  API  representa  uma  complicação  potencialmente  mortal  após  o  TC.  Um  diagnós-
tico precoce  e  a  iniciação  de  um  tratamento  rapidamente  agressivo  constituem  a  pedra  angular
para  uma  melhor  sobrevivência.
© 2019  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  España,  S.L.U.  Este é  um

















































nfection  remains  a  major  complication  among  transplant
ecipients, causing  approximately  20%  of  deaths  in  the  first
ear after  transplantation,  as  well  as  being  a  major  cause  of
ong-term morbidity  and  mortality.  In  solid  organs,  such  as
ardiac transplantation,  in  which  immunosuppressants  are
rescribed indefinitely,  physicians  and  patients  perpetually
egotiate the  delicate  balance  between  the  risks  of  graft
ejection and  infection.1 In  this  immunosuppressed  popu-
ation, Aspergillus  spp.  --  an  opportunistic  pathogen  --  can
ause aggressive  infections  including  sinusitis,  tracheobron-
hitis, pneumonia,  necrotizing  cellulitis,  brain  abscess,  or
isseminated disease.  In  heart  transplant  (HT)  recipients,
spergillus spp.  has  been  reported  as  the  most  common
ause of  invasive  fungal  infection  and  frequently  causes
neumonia2 with  a  high  attributable  mortality,  ranging  from
3% to  78%.3--5 Although  invasive  pulmonary  aspergillosis
IPA) is  a  serious  disease  in  this  population,  little  is  known
bout its  natural  history.  The  aim  of  this  study  was  to  fur-
her establish  the  characteristics  of  IPA  infections  and  their
utcomes in  our  center.
ethodse  conducted  a  retrospective  chart  review  of  patients  who





998  and  2016  and  who  subsequently  developed  IPA.  Cases
ere identified  according  to  the  clinical  practice  guidelines
f the  Infectious  Diseases  Society  of  America  for  IPA6 and
he revised  EORTC/MSG  criteria  for  defining  invasive  fungal
nfection, including  IPA.7 The  diagnosis  was  considered  def-
nite when  the  patient  had  positive  histology  and  culture  of
 sample  obtained  from  the  same  site,  or  negative  histology
or not  performed)  and  positive  culture  results  of  a  sample
btained by  protocol-specified  invasive  techniques  such  as
ronchoalveolar lavage  (BAL).  A  galactomannan  index  of  1
r higher  was  regarded  as  positive  and  suggested  a  diagnosis
f IPA.
Data collection  included  age,  gender,  primary  cardiac
iagnosis, date  of  transplantation,  immunosuppressant  reg-
men, cytomegalovirus  (CMV)  serological  status,  antifungal
rophylaxis, known  risk  factors  for  IPA  (including  neutrope-
ia), radiographic  features,  serum  galactomannan  level,
ronchoscopy and  microbiology  data  (Tables  1  and  2).
At  our  institution,  by  protocol  all  patients  receive
nduction therapy  with  basiliximab  and  high  doses  of  cor-
icosteroids. Basiliximab  is  administered  4-6  hours  after
eaning from  cardiopulmonary  bypass.  Initiation  of  cal-
ineurin inhibitors  is  delayed  until  day  3  post-HT.
aintenance immunosuppressive  therapy  consists  of  corti-
osteroids, calcineurin  inhibitors  and  cell  cycle  inhibitors.
his immunosuppression  regimen  is  based  on  the  Interna-
ional Society  of  Heart  and  Lung  Transplantation  guidelines
or the  care  of  heart  transplant  recipients.8
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Table  1  Demographic  and  clinical  characteristics  and  laboratory  features  of  the  study  population.








1  59  Male  Dilated  car-
diomyopathy
5 60  Cyclosporine  +
mycophenolate
9.5/-  1.6
2 70  Male  Dilated  car-
diomyopathy
12 50  Tacrolimus  +
mycophenolate
14.5/-  0.9
3 51  Male  Chagas  car-
diomyopathy
116 15  Tacrolimus  +
azathioprine
8.1/-  1.0
4 61  Male  Valvular  car-
diomyopathy
189 7.5  Tacrolimus  +
mycophenolate
2.9/1.2  1






































In  our  HT  protocol,  all  patients  without  risk  factors  for
infection by  filamentous  fungi  are  prescribed  fluconazole
100 mg/day  during  the  first  month,  from  day  1  post-
transplant, while  patients  who  are  at  risk  for  such  infection
(at least  one  of  the  following  risk  factors:  administration  of
immunosuppression; acute  renal  failure  requiring  hemodial-
ysis; colonization  by  filamentous  fungi  such  as  Aspergillus;
retransplant or  double  transplant  [heart  and  kidney  or  heart
and liver])  receive  antifungal  prophylaxis  with  liposomal
amphotericin B  or  micafungin.
In  all  patients  under  antifungal  prophylaxis,  fungal
culture and  staining  with  calcium  fluoride  from  sputum  or
respiratory secretions,  chest  X-rays  and  serum  galactoman-
nan testing  for  Aspergillus  are  performed  once  a  week  while
hospitalized. If  the  chest  X-ray  is  doubtful,  high-resolution
chest computed  tomography  (CT)  is  performed.
Following  hospital  discharge,  patients  are  followed  at
our center  every  month  for  the  first  six  months  after  HT,
every two  months  from  the  sixth  to  the  twelfth  month,  and
then every  six  months  indefinitely.  At  each  visit  a  compre-
hensive clinical  assessment  is  performed  including  routine
laboratory tests  and  a  chest  X-ray.
Results
Among  328  HTs  performed  between  1998  and  2016,  we  iden-
tified five  cases  of  IPA.  All  cases  were  male,  and  mean
age was  62  years  (range  59-71  years).  The  most  common
indication for  HT  was  non-ischemic  dilated  cardiomyopathy.
Antifungal prophylaxis  was  started  in  all  patients,  but  two
patients did  not  complete  the  course  since  IPA  was  diag-
nosed in  the  first  30  days  after  transplantation.  One  patient
required prophylaxis  with  micafungin  due  to  acute  renal
failure.
The median  time  from  transplantation  to  diagnosis  was  55
days. Productive  cough  was  reported  as  the  main  symptom
in two  patients,  one  patient  presented  atypical  chest  pain
and the  other  two  were  asymptomatic.  In  one  of  the  asymp-
tomatic patients  the  diagnosis  was  suspected  from  abnormal
findings (unilateral  nodular  opacities)  on  chest  X-ray  dur-
ing a  routine  monthly  follow-up  visit.  In  all  patients,  the
radiological assessment  was  based  on  chest  X-ray  and  chest
CT. The  most  commonly  reported  radiographic  abnormality






Figure  1).  Halo  sign  was  observed  in  one  case  (Figure  1B).
erum galactomannan  level  was  abnormally  high  in  three  out
f  five  patients.  Bronchoscopy  was  performed  in  all  patients
nd A.  fumigatus  was  isolated  on  BAL  culture  in  four  cases.
spergillus was  demonstrated  by  polymerase  chain  reaction
PCR) in  the  patient  in  whom  nodular  lesions  on  the  chest
-ray aroused  suspicion  of  IPA.
Initial  antifungal  treatment  included  amphotericin  in  four
atients, subsequently  changed  to  voriconazole  in  three
ases, and  posaconazole  in  one  patient,  with  total  treatment
asting an  average  of  12  months.  Two  patients  required  the
ddition of  caspofungin  and  one  of  anidulafungin  as  salvage
herapy. Neutropenia  was  found  in  only  one  patient.  Renal
ailure, defined  as  creatinine  >1.5  mg/dl,  was  observed
n two  patients,  and  concurrent  CMV  infection  in  three
atients. All  patients  were  alive  after  a mean  follow-up  of
8 months.
iscussion
ince  the  introduction  of  HT  as  a  therapeutic  modality
or end-stage  heart  failure  in  1968,  Aspergillus  has  been
ecognized as  a  major  opportunistic  pathogen  with  a  high
ttributable mortality.5 Our  series  of  five  IPA  cases  shows
nusually low  mortality.  There  are  several  possible  reasons
or this.  First,  the  number  of  reported  cases  is  small;  how-
ver, 100%  survival  appears  optimistically  high,  and  some
atality would  be  expected.  Second,  two  patients  were
symptomatic at  the  time  of  diagnosis,  both  with  negative
erum galactomannan,  which  indicates  that  treatment  was
nitiated in  good  time.  Also,  four  patients  received  combined
reatment with  two  antifungals  and  only  one  patient  was
reated with  just  one  drug.
The  known  risk  factors  for  IPA  in  HT  recipients  include
solation of  A.  fumigatus  in  respiratory  tract  cultures  prior
o HT,  reoperation,  CMV  disease,  post-transplant  hemodial-
sis, and  cases  of  IPA  in  the  institution  in  the  two  months
efore transplantation.7 In  a study  by  Muñoz  et  al.,4 IPA-
elated mortality  was  11/17  (65%),  and  total  mortality  was
7/27 (63%),  but  this  cohort  presented  a  high  proportion  of
isk factors  for  IPA:  hemodialysis  in  19%,  bacterial  infection
n 63%,  and  rejection  episode  in  44%.  Also  in  this  cohort,  82%
f patients  received  either  OKT3  or  anti-thymocyte  globu-









Table  2  Clinical  course  and  treatment.










Chest  X-ray  CT  scan  Treatment  ISHLT  rejection
grade
1  Asymptomatic  0.13  Yes  BAL  culture:
Aspergillus
fumigatus
Micafungin  None  Multiple
micronodular
opacities
Amphotericin  B  1A
2 Productive
cough







opacities  and  a







































Amphotericin  B  1A
BAL: bronchoalveolar lavage; CT: computed tomography; ISHLT: International Society of Heart and Lung Transplantation.; PCR: polymerase chain reaction.












Figure  1  Chest  computed  tomography  showing  (A)  multiple  n
pulmonary  aspergillosis  (yellow  arrow).
immunosuppression,  the  higher  the  risk  of  infection.  None
of our  patients  needed  hemodialysis,  nor  were  there  any
rejection episodes  requiring  an  increase  in  immunosuppres-
sion. Likewise,  our  patients  received  basiliximab  instead  of
OKT3 or  anti-thymocyte  globulin.  Baxiliximab  is  associated
with fewer  infections  overall  than  OKT3  or  anti-thymocyte
globulin in  solid  organ  transplantation.9
Although  this  case  series  could  have  suffered  from  pub-
lication bias,  we  consider  our  results  to  be  due  to  early
diagnosis based  on  serum  galactomannan  level  and  prompt
bronchoscopy followed  by  initiation  of  aggressive  treat-
ment, as  well  as  the  patients’  clinical  characteristics.  Our
findings can  be  summarized  as  improved  outcomes  resulting
from early  diagnosis,  which  has  also  been  shown  in  patients
with blood  cancer  and  invasive  fungal  infections.
Finally,  it  appears  that,  as  in  many  other  fields  of
medicine, patients’  prognosis  is  improving  as  we  learn  more
about complications  and  as  new  diagnostic  techniques  lead
to earlier  initiation  of  modern  therapeutic  strategies.  As
Montoya et  al.3 concluded,  patients  suffering  IPA  in  recent
years may  have  a  better  prognosis  than  those  treated  before.
Have we  reached  the  point  when  mortality  from  IPA  is
decreasing?
Conclusion
IPA  is  a  potentially  lethal  complication  after  HT.  Early  diag-
nosis and  prompt  initiation  of  aggressive  treatment  are  the
cornerstone of  better  survival.Conflicts of interest
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